Tumor-Infiltrating PD-L1+ Neutrophils Induced by GM-CSF Suppress T Cell Function in Laryngeal Squamous Cell Carcinoma and Predict Unfavorable Prognosis
Di Tang,Duo Zhang,Yu Heng,Xiao-Ke Zhu,Han-Qing Lin,Jian Zhou,Lei Tao,Li-Ming Lu
DOI: https://doi.org/10.2147/JIR.S347777
IF: 4.5
2022-02-16
Journal of Inflammation Research
Abstract:Di Tang, 1, &ast Duo Zhang, 1, &ast Yu Heng, 1 Xiao-Ke Zhu, 1 Han-Qing Lin, 1 Jian Zhou, 1 Lei Tao, 1 Li-Ming Lu 2 1 Department of Otorhinolaryngology and ENT Institute, Eye & ENT Hospital, Fudan University, Shanghai, People's Republic of China; 2 Shanghai Institute of Immunology, Shanghai Jiaotong University School of Medicine, Shanghai, People's Republic of China &astThese authors contributed equally to this work Correspondence: Li-Ming Lu, Shanghai Institute of Immunology, Shanghai Jiaotong University School of Medicine, 280 South Chongqing Road, Shanghai, 200025, People's Republic of China, Tel +86-13916235624, Fax +86-021-63846383, Email Lei Tao, ENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, 83 Fenyang Road, Shanghai, 200031, People's Republic of China, Tel +86-13916944810, Email Purpose: Chronic inflammation contributes to tumor initiation, progression, and immune escape. Neutrophils are the major component of inflammatory response and participate in the tumorigenesis process. However, compared to other immune cells in the tumor microenvironment of laryngeal squamous cell carcinoma (LSCC), neutrophils, especially the tumor-associated neutrophils (TANs), have not yet been comprehensively explored. The mechanism for regulating the crosstalk between TANs and tumor cells still remains unclear. Materials and Methods: The distribution profiles and phenotypic features of neutrophils and other inflammatory immune cell populations from a large LSCC patient cohort were systemically analyzed. Co-culturing of peripheral blood associated neutrophils (PANs) and TANs with PBMCs was performed, and the immunosuppression effect on T-cells was examined. Results: LSCC microenvironment is highly inflammatory with remarkable TANs infiltration, which is often associated with unfavorable prognosis and advanced clinical stage. We find that TANs in LSCC display morphologically immature and lower apoptosis, exhibit distinctively immunosuppressive phenotype of high PD-L1, and suppress CD8 + T lymphocytes proliferation and activation. We subsequently discover that PD-L1 + TANs induced by LSCC-derived GM-CSF potently impair CD8 + T-cells proliferation and cytokines production function, which are partially blocked by a PD-L1-neutralizing antibody. Clinical data further support GM-CSF as an unfavorable prognostic biomarker and reveal a potential association with inflammatory immune cell infiltration, in particular neutrophils. Conclusion: Tumor-infiltrating PD-L1+ neutrophils induced by LSCC-derived GM-CSF suppress T cell proliferation and activation in the inflammatory microenvironment of LSCC and predict unfavorable prognosis. These TANs cripple antitumor T cell immunity and promote tumor progression. Our findings provide a basis for targeting PD-L1+TANs or GM-CSF as a new immunotherapeutic strategy for LSCC. Keywords: laryngeal squamous cell carcinoma, LSCC, tumor-associated neutrophils, TANs, PD-L1, inflammatory microenvironment, immune suppression, granulocyte-macrophage colony stimulating factor, GM-CSF Laryngeal squamous cell carcinoma (LSCC) represents one of the most common head and neck malignant tumors. According to the latest published global cancer statistics in 2018 by the International Agency for Research on Cancer, the morbidity and mortality of laryngeal cancer approximately accounted for 1.0% of all cancers. 1 In China, it was estimated that there were 26,400 new cases of laryngeal cancers and 14,500 cancer-related deaths in 2015. 2 Despite continuous improvements in surgery, radiotherapy, chemotherapy and other multimodality treatments, the 5-year survival rate of laryngeal cancer remains unsatisfactory low from 1975 to 2015 (National Cancer Institute. SEER Stat Fact Sheets: Larynx Cancer. Available from: https://seer.cancer.gov/statfacts/html/laryn.html ). The immune-checkpoint inhibitors (ICIs) exempted by anti-PD-1/PD-L1 mAbs are being used for the treatment of head and neck squamous cell carcinoma (HNSC), kidney carcinoma, melanoma, lung cancer, gastric cancer and hepatocellular carcinoma. 3 However, the objective response rates to anti-PD-1 and anti-PD-L1 immunotherapies remain largely refractory. The complete response and partial response rates of PD-1 blocking agents for patients with recurrent or metastatic HNSC progressing after platinum-based chemotherapy are 5% and 11%, respectively. 4 The curative effect of ICIs differs greatly in various tumors and patients partly due to tumor mutation burdens and other individual patient variations, such as tumor mi -Abstract Truncated-
immunology